Deep Track Capital, LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Deep Track Capital, LP reported 66 stock positions worth $6.8 billion. Its top holding was Guardant Health (GH) at 7.5% of the portfolio, followed by Immunovant (IMVT, 5.3%) and Structure Therapeutics (GPCR, 3.7%). Compared with Q1 2026, it opened 18 new positions, sold out of 14, added to 22 and reduced 15. The biggest buy was a new position in Alnylam Pharmaceuticals (ALNY) and the biggest sale an exit from Apellis Pharmaceuticals (APLS).
- Most Recent 13F
- Q2 2026
- Location
- GREENWICH, CT
- CIK
- 0001856083
- Portfolio Value
- $6.8B (Q2 2026)
- SEC Filing
- 0001856083-26-000004 ↗ filed Aug 14, 2026
Holdings Value
Holdings 66 stocks · $6.8B
| GH Guardant Health Inc. | 7.50% | 3,393,312 | $509.1M | Add +1.6% |
| IMVT Immunovant Inc. | 5.30% | 9,341,151 | $359.9M | Reduce -19.0% |
| GPCR Structure Therapeutics Inc. | 3.75% | 4,740,072 | $254.4M | Add +10.8% |
| PCVX Vaxcyte Inc. | 3.68% | 4,300,000 | $250.0M | No change |
| ALNY Alnylam Pharmaceuticals Inc. | 3.66% | 825,000 | $248.3M | New |
| MANE Veradermics Inc. | 3.62% | 2,000,000 | $245.9M | Add +300.0% |
| TARS Tarsus Pharmaceuticals Inc. | 3.40% | 3,666,768 | $230.8M | Add +1.9% |
| NUVL Nuvalent Inc. Class A | 3.24% | 1,783,322 | $220.2M | Add +29.6% |
| ALKS Alkermes PLC | 3.09% | 4,000,000 | $209.6M | Add +11.4% |
| OCUL Ocular Therapeutix Inc. | 2.85% | 19,686,282 | $193.3M | No change |
| BMRN Biomarin Pharmaceutical Inc. | 2.79% | 3,307,481 | $189.3M | Add +187.6% |
| NRIX Nurix Therapeutics Inc. | 2.76% | 7,736,455 | $187.7M | Add +21.9% |
| ORKA Oruka Therapeutics Inc. | 2.70% | 1,926,000 | $183.3M | Reduce -5.3% |
| ALMS Alumis Inc. | 2.63% | 6,348,558 | $178.6M | Reduce -6.3% |
| IONS Ionis Pharmaceuticals Inc. | 2.57% | 2,200,000 | $174.4M | Add +12.8% |
| CMPS Compass Pathways PLC | 2.54% | 12,161,496 | $172.1M | No change |
| VERA Vera Therapeutics Inc. | 2.53% | 4,000,000 | $171.6M | Reduce -2.6% |
| AXSM Axsome Therapeutics Inc. | 2.52% | 700,000 | $171.3M | Reduce -36.4% |
| GMAB Genmab A/S -SP ADR | 2.29% | 5,650,000 | $155.2M | Add +54.2% |
| MLTX Moonlake Immunotherapeutics | 2.01% | 6,999,025 | $136.3M | Add +9.2% |
| COAG Hemab Therapeutics Holdings | 1.95% | 3,602,093 | $132.3M | New |
| TNGX Tango Therapeutics Inc. | 1.93% | 4,200,000 | $131.3M | Add +52.7% |
| DFTX Definium Therapeutics Inc. | 1.91% | 2,750,000 | $129.4M | Reduce -8.3% |
| GRAL Grail Inc. | 1.85% | 1,834,944 | $125.3M | Add +6.5% |
| BCAX Bicara Therapeutics Inc. | 1.79% | 4,100,000 | $121.7M | Add +0.9% |
| MAZE Maze Therapeutics Inc. | 1.64% | 3,732,569 | $111.4M | Add +7.3% |
| CLDX Celldex Therapeutics Inc. | 1.61% | 2,939,151 | $109.4M | Add +128.9% |
| LBRX LB Pharmaceuticals Inc. | 1.60% | 3,352,804 | $108.8M | No change |
| MBX MBX Biosciences Inc. | 1.41% | 1,732,569 | $95.6M | Reduce -37.2% |
| GHRS GH Research PLC | 1.32% | 3,333,334 | $89.6M | New |
| COGT Cogent Biosciences Inc. | 1.14% | 2,000,000 | $77.4M | Add +100.0% |
| ATAI Ataibeckley Inc. | 1.12% | 14,417,442 | $76.0M | Add +20.1% |
| UTHR United Therapeutics Corp. | 0.99% | 123,616 | $67.0M | New |
| AVTX Avalo Therapeutics Inc. | 0.98% | 3,610,000 | $66.7M | New |
| VRDN Viridian Therapeutics Inc. | 0.97% | 3,592,740 | $66.0M | Add +157.7% |
| CYTK Cytokinetics Inc. | 0.88% | 700,000 | $59.6M | Reduce -49.1% |
| ALT Altimmune Inc. | 0.86% | 19,250,000 | $58.5M | New |
| PSNL Personalis Inc. | 0.79% | 4,000,000 | $53.6M | Add +33.3% |
| ACRS Aclaris Therapeutics Inc. | 0.73% | 9,345,000 | $49.4M | No change |
| CRMD Cormedix Inc. | 0.73% | 6,274,076 | $49.3M | No change |
| WGS Genedx Holdings Corp. | 0.71% | 700,000 | $48.1M | New |
| HROW Harrow Inc. | 0.61% | 969,000 | $41.2M | New |
| CRVS Corvus Pharmaceuticals Inc. | 0.55% | 2,491,939 | $37.2M | Add +0.0% |
| SLDB Solid Biosciences Inc. | 0.52% | 3,565,062 | $35.6M | No change |
| BEAM Beam Therapeutics Inc. | 0.51% | 1,000,000 | $34.3M | Add +21.8% |
| DYN Dyne Therapeutics Inc. | 0.49% | 1,500,000 | $33.3M | Reduce -25.0% |
| IMMX Immix Biopharma Inc. | 0.42% | 2,775,000 | $28.6M | New |
| XFOR X4 Pharmaceuticals Inc. | 0.40% | 5,878,757 | $27.5M | Reduce -7.3% |
| STTK Shattuck Labs Inc. | 0.38% | 3,706,734 | $25.7M | New |
| MNKD Mannkind Corp. | 0.38% | 6,000,000 | $25.6M | New |
| IPSC Century Therapeutics Inc. | 0.34% | 9,462,645 | $23.2M | Reduce -0.3% |
| GENB Generate Biomedicines Inc. | 0.33% | 1,333,815 | $22.5M | New |
| VSTM Verastem Inc. | 0.32% | 5,740,850 | $21.9M | No change |
| KURA Kura Oncology Inc. | 0.32% | 1,978,565 | $21.7M | Reduce -25.1% |
| ENTA Enanta Pharmaceuticals Inc. | 0.31% | 1,444,167 | $21.1M | Reduce -26.2% |
| NKTR Nektar Therapeutics | 0.31% | 300,000 | $20.9M | New |
| OLMA Olema Pharmaceuticals Inc. | 0.28% | 1,500,000 | $18.8M | New |
| KLRA Kailera Therapeutics Inc. | 0.23% | 700,000 | $15.4M | New |
| KARD Kardigan Inc. | 0.21% | 600,000 | $14.3M | New |
| ELVN Enliven Therapeutics Inc. | 0.17% | 225,000 | $11.4M | New |
| PMN Promis Neurosciences Inc. | 0.16% | 835,655 | $11.0M | No change |
| IMCR Immunocore Holdings PLC-ADR | 0.15% | 311,218 | $9.9M | Reduce -83.9% |
| XNCR Xencor Inc. | 0.14% | 593,551 | $9.6M | New |
| CNTX Context Therapeutics Inc. | 0.06% | 7,419,355 | $4.1M | No change |
| IVA Inventiva SA - ADR | 0.04% | 800,000 | $3.0M | Reduce -34.6% |
| ALGS Aligos Therapeutics Inc. | 0.04% | 444,110 | $2.6M | No change |
Options reported separately and not counted above: GMAB calls ($82.4M).
Portfolio Sells Q1 2026 → Q2 2026
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −3.76 |
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −2.59 |
| AXSM Axsome Therapeutics Inc. | Reduce -36.4% | 2.52% | −1.31 |
| BBIO Bridgebio Pharma Inc. | Sold out | 0.00% | −1.29 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −1.17 |
| IMCR Immunocore Holdings PLC-ADR | Reduce -83.9% | 0.15% | −1.06 |
| CYTK Cytokinetics Inc. | Reduce -49.1% | 0.88% | −0.99 |
| GERN Geron Corp. | Sold out | 0.00% | −0.98 |
| ANIP Ani Pharmaceuticals Inc. | Sold out | 0.00% | −0.95 |
| VERA Vera Therapeutics Inc. | Reduce -2.6% | 2.53% | −0.88 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −0.75 |
| ENGN Engene Holdings Inc. | Sold out | 0.00% | −0.62 |
| IMVT Immunovant Inc. | Reduce -19.0% | 5.30% | −0.61 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −0.49 |
| ALMS Alumis Inc. | Reduce -6.3% | 2.63% | −0.45 |
| JANX Janux Therapeutics Inc. | Sold out | 0.00% | −0.34 |
| MBX MBX Biosciences Inc. | Reduce -37.2% | 1.41% | −0.29 |
| DYN Dyne Therapeutics Inc. | Reduce -25.0% | 0.49% | −0.26 |
| ENTA Enanta Pharmaceuticals Inc. | Reduce -26.2% | 0.31% | −0.20 |
| CBIO Crescent Biopharma Inc. | Sold out | 0.00% | −0.17 |
| LRMR Larimar Therapeutics Inc. | Sold out | 0.00% | −0.14 |
| XFOR X4 Pharmaceuticals Inc. | Reduce -7.3% | 0.40% | −0.14 |
| HELP Cybin Inc. | Sold out | 0.00% | −0.13 |
| KURA Kura Oncology Inc. | Reduce -25.1% | 0.32% | −0.12 |
| IPSC Century Therapeutics Inc. | Reduce -0.3% | 0.34% | −0.10 |
| IVA Inventiva SA - ADR | Reduce -34.6% | 0.04% | −0.10 |
| BLLN Billiontoone Inc. Class A | Sold out | 0.00% | −0.08 |
| ORKA Oruka Therapeutics Inc. | Reduce -5.3% | 2.70% | +0.64 |
| DFTX Definium Therapeutics Inc. | Reduce -8.3% | 1.91% | +0.74 |
Portfolio Buys Q1 2026 → Q2 2026
| ALNY Alnylam Pharmaceuticals Inc. | New | 3.66% | +3.66 |
| MANE Veradermics Inc. | Add +300.0% | 3.62% | +2.97 |
| COAG Hemab Therapeutics Holdings | New | 1.95% | +1.95 |
| BMRN Biomarin Pharmaceutical Inc. | Add +187.6% | 2.79% | +1.45 |
| GHRS GH Research PLC | New | 1.32% | +1.32 |
| GH Guardant Health Inc. | Add +1.6% | 7.50% | +1.14 |
| UTHR United Therapeutics Corp. | New | 0.99% | +0.99 |
| AVTX Avalo Therapeutics Inc. | New | 0.98% | +0.98 |
| ALT Altimmune Inc. | New | 0.86% | +0.86 |
| CLDX Celldex Therapeutics Inc. | Add +128.9% | 1.61% | +0.77 |
| TNGX Tango Therapeutics Inc. | Add +52.7% | 1.93% | +0.75 |
| NRIX Nurix Therapeutics Inc. | Add +21.9% | 2.76% | +0.74 |
| WGS Genedx Holdings Corp. | New | 0.71% | +0.71 |
| HROW Harrow Inc. | New | 0.61% | +0.61 |
| ALKS Alkermes PLC | Add +11.4% | 3.09% | +0.47 |
| IMMX Immix Biopharma Inc. | New | 0.42% | +0.42 |
| VRDN Viridian Therapeutics Inc. | Add +157.7% | 0.97% | +0.41 |
| PSNL Personalis Inc. | Add +33.3% | 0.79% | +0.40 |
| STTK Shattuck Labs Inc. | New | 0.38% | +0.38 |
| MNKD Mannkind Corp. | New | 0.38% | +0.38 |
| COGT Cogent Biosciences Inc. | Add +100.0% | 1.14% | +0.35 |
| NUVL Nuvalent Inc. Class A | Add +29.6% | 3.24% | +0.34 |
| GENB Generate Biomedicines Inc. | New | 0.33% | +0.33 |
| NKTR Nektar Therapeutics | New | 0.31% | +0.31 |
| OLMA Olema Pharmaceuticals Inc. | New | 0.28% | +0.28 |
| GMAB Genmab A/S -SP ADR | Add +54.2% | 2.29% | +0.26 |
| ATAI Ataibeckley Inc. | Add +20.1% | 1.12% | +0.24 |
| KLRA Kailera Therapeutics Inc. | New | 0.23% | +0.23 |
| KARD Kardigan Inc. | New | 0.21% | +0.21 |
| ELVN Enliven Therapeutics Inc. | New | 0.17% | +0.17 |
| XNCR Xencor Inc. | New | 0.14% | +0.14 |
| BCAX Bicara Therapeutics Inc. | Add +0.9% | 1.79% | +0.13 |
| BEAM Beam Therapeutics Inc. | Add +21.8% | 0.51% | +0.10 |
| GRAL Grail Inc. | Add +6.5% | 1.85% | +0.01 |
| CRVS Corvus Pharmaceuticals Inc. | Add +0.0% | 0.55% | −0.20 |
| IONS Ionis Pharmaceuticals Inc. | Add +12.8% | 2.57% | −0.45 |
| MLTX Moonlake Immunotherapeutics | Add +9.2% | 2.01% | −0.46 |
| MAZE Maze Therapeutics Inc. | Add +7.3% | 1.64% | −0.50 |
| GPCR Structure Therapeutics Inc. | Add +10.8% | 3.75% | −0.51 |
| TARS Tarsus Pharmaceuticals Inc. | Add +1.9% | 3.40% | −1.81 |
Options Activity Q1 2026 → Q2 2026
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 10,000,000 | $1.3Bbefore exit |
| GMAB Genmab A/S -SP ADR | call | New | 3,000,000 | $82.4M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 66 | $6.8B | GH, IMVT, GPCR, PCVX, ALNY |
| Q1 2026 | 62 | $4.8B | GH, IMVT, TARS, PCVX, GPCR |
| Q4 2025 | 53 | $4.4B | IMVT, GH, GPCR, TARS, DVAX |
| Q3 2025 | 56 | $3.6B | GH, IONS, CYTK, AKRO, APLS |
| Q2 2025 | 65 | $3.1B | GH, IONS, PTGX, DVAX, INSM |
| Q1 2025 | 69 | $3.1B | ITCI, GH, DVAX, IMVT, PTGX |
| Q4 2024 | 61 | $2.7B | DVAX, GH, ITCI, IMVT, APLS |
| Q3 2024 | 69 | $3.1B | ARGX, DVAX, GH, APLS, IMVT |
| Q2 2024 | 67 | $3.3B | AMGN, ARGX, AXSM, DYN, SWTX |
| Q1 2024 | 65 | $3.5B | SWTX, AMGN, APGE, INSM, DYN |